BREAKINGMay 5, 2026

RFK Jr. Wants To Wean Some Americans Off Antidepressants

Health Secretary Robert F. Kennedy Jr. announced a federal initiative at the Mental Health and Overmedicalization Summit to reduce American reliance on antidepressants, including SSRIs like Prozac, Zoloft, and Lexapro. The plan creates new Medicare and Medicaid reimbursements for clinicians who help patients discontinue psychiatric medications and introduces federal training modules on tapering patients off drugs safely. Kennedy framed the effort as promoting non-pharmacological alternatives like therapy, exercise, diet, and social connection.

X LinkedIn Facebook Threads WhatsApp Reddit

⚡Both sides have significant internal splits on this story. Arguments below represent the dominant positions — see The Divide below for the full picture.

Should the government actively discourage Americans from taking antidepressants that their doctors prescribed? RFK Jr.'s push to reduce psychiatric medication use raises the question: who decides when a drug is doing more harm than good — the person taking it, their doctor, or a public health official?

Not familiar with this story? Get context →

Deprescribing incentives pressure vulnerable patients

Conservative

1 in 6 Americans on SSRIs isn't a treatment success — it's a question we've stopped asking. Payment structures that made drug visits faster and cheaper than therapy sessions drove that number up, and Kennedy is trying to use the same reimbursement lever to push back. The underlying logic is defensible.

Liberal

You just made the case against the policy. If reimbursement codes drove overprescribing, then a new code specifically rewarding deprescribing doesn't fix the problem — it reproduces it with a different directional bias. The 68-year-old on Medicaid in rural Arkansas whose doctor now gets paid more to take her off Lexapro than to keep her on it isn't experiencing better medicine. She's experiencing a different institutional pressure with fewer resources to resist it.

Conservative

That's a real risk, and it's the strongest objection to this policy — but it's an objection to implementation, not to the premise. The same argument could have been used to block every Medicare quality incentive ever designed.

Liberal

Quality incentives reward documented outcomes. A deprescribing code rewards the act of discontinuing medication regardless of what happens to the patient afterward — that's not a comparable structure.

Lancet evidence base versus federal action

Conservative

The 2019 Lancet meta-analysis — 500 trials, 116,000 patients — confirmed antidepressants outperform placebo for major depression across every drug studied. A federal initiative that treats that finding as provisional while paying clinicians to reverse its clinical applications isn't engaging with the science. It's overriding it.

Liberal

The Lancet study established efficacy for major depression — it didn't establish that the 1-in-6 Americans currently prescribed SSRIs all have major depression. Those are different claims. If a meaningful portion of current prescriptions are for mild situational distress where therapy has comparable outcomes, the evidence base doesn't immunize the prescribing rate from scrutiny.

Conservative

That's a fair distinction, but Kennedy didn't build a policy targeting mild situational prescriptions — he built one that applies across the Medicaid population broadly, which includes people with serious, recurrent major depression.

Liberal

Exactly — the precision the evidence demands is absent from the policy, and the patients who pay for that imprecision are the ones with the least ability to push back.

Kennedy's heroin claim poisons the initiative

Conservative

Kennedy said antidepressants are harder to quit than heroin. NPR, pharmacologists, and clinicians across the political spectrum confirmed that's medically false. Opioid withdrawal carries documented mortality risk from acute physiological dependence. SSRI discontinuation is real and sometimes severe — but it is clinically distinct. When the architect of this initiative opens with a fabrication, the policy that follows can't be cleanly separated from the misinformation that launched it.

Liberal

The claim was wrong, and he should retract it. But you're running the logic backward — if the statement is false, it's false because the science says so, which means we're both agreeing the science is the arbiter here. The question is whether that one false statement disqualifies every downstream policy action, or whether the policy lives or dies on its own merits.

Conservative

It matters because false claims normalize stigma, stigma generates political momentum for deprescribing, and that momentum reaches patients before the evidence review does — that's a causal chain, not a rhetorical one.

Liberal

You're conceding the statement was wrong and the logic was wrong, which means the political energy behind this initiative was built on a falsehood — that's not a procedural objection, that's the foundation.

Therapy alternatives must precede deprescribing

Conservative

Even if the overprescribing critique is correct, you can't tell a single mother in Mississippi to substitute therapy for Zoloft when the nearest in-network therapist has a four-month waitlist. The sequencing isn't a detail — it's the entire moral weight of the policy. Build the alternative infrastructure first, then create deprescribing incentives.

Liberal

That sequencing argument, taken seriously, means no reform ever happens — because the infrastructure gap never fully closes. Medicaid coverage for cognitive behavioral therapy has been advocated for decades without the political will to fund it. If that gap is the prerequisite, Kennedy's critics are holding the reform hostage to a condition they've never actually funded.

Conservative

The difference is that expanding therapy access creates options; deprescribing incentives remove them. Those aren't symmetrical actions with interchangeable timelines.

Liberal

Right — and a policy that removes access before adding it isn't reform, it's subtraction with a press release.

Teenage suicide risk is not hypothetical

Conservative

STAT News specifically flagged that Kennedy's initiative poses life-threatening risk to teenagers — a population where the FDA itself issued a black-box warning about suicidality, but where antidepressant access is also directly linked to suicide prevention outcomes. That tension requires precision this policy doesn't have.

Liberal

The black-box warning is real, and so is the evidence that untreated adolescent depression carries suicide risk. But those two facts don't cancel each other — they demand careful clinical judgment, which is exactly what you get less of when you introduce financial incentives that push in one direction. A blanket deprescribing code is the opposite of careful.

Conservative

We agree on the clinical requirement. The dispute is whether the incentive structure Kennedy has proposed is capable of delivering it — and given what he said about heroin in January, there's no evidence it was designed with that care.

Liberal

A policy aimed at a population where the downside is suicide and the architect compared the drugs to heroin is not a policy built for careful clinical judgment.

Conservative's hardest question

Creating pay incentives for clinicians to deprescribe could pressure the most vulnerable Medicaid and Medicare patients — those with fewest alternatives — into discontinuing medications they genuinely need, substituting pharmaceutical industry bias with a federal deprescribing bias that is equally indifferent to individual patient welfare.

Liberal's hardest question

The legitimate version of the overprescribing critique — that SSRIs are sometimes reflexively prescribed for mild situational depression where therapy would be both safer and more durable — is supported by credible researchers outside the pharmaceutical industry. If the policy were carefully designed to expand therapy access first and restrict deprescribing incentives to genuinely appropriate clinical contexts with full psychiatric supervision, it would be harder to oppose on principled grounds. The liberal case depends partly on Kennedy being the wrong person executing a badly sequenced version of a reform that isn't inherently illegitimate.

The Divide

*Kennedy's deprescribing push has fractured both parties—some see pharmaceutical accountability, others see dangerous government meddling in medicine.*

MAGA/POPULIST-RIGHT

Supports the initiative as exposing pharmaceutical industry capture and restoring natural health alternatives.

ESTABLISHMENT CONSERVATIVE

Opposes federal reimbursement levers steering clinical decisions, viewing it as government overreach into doctor-patient relationships.

PROGRESSIVE/SQUAD

Frames the initiative as authoritarian dismantling of public health institutions that harms vulnerable populations.

CENTRIST DEMOCRAT

Criticizes Kennedy's misinformation while leaving room for bipartisan work on mental health access based on medical consensus.

The Verdict

Both sides agree

Both sides accept that Medicare and Medicaid reimbursement structures functionally shape clinical behavior at scale, and that financial incentives will disproportionately influence lower-income patients with fewer resources to seek alternatives or second opinions.

The real conflict

The factual dispute over Kennedy's heroin claim: Conservatives implicitly accept NPR's and pharmacologists' characterization that the claim is medically false, while also arguing this is a rhetorical flourish that shouldn't disable the underlying policy critique; liberals treat the false claim as foundational evidence that Kennedy lacks the medical precision required to implement a policy affecting 54 million Americans.

What nobody has answered

If SSRIs are genuinely overprescribed for mild-to-moderate depression (a claim neither side fully rejects), why should the federal government correct this via incentives to clinicians to discontinue medications rather than via expansion of cognitive behavioral therapy access, and why would the deprescribing route be chosen when it requires patients to trust a system that demonstrably under-resources alternatives in their zip codes?

Sources

RFK Jr. Wants To Wean Some Americans Off Antidepressants

More debates